Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088452 · ClinicalTrials.gov registry record · Phase 3
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
A Phase 3 study of Epilepsy and Seizures, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT00088452 is a Phase 3 study of Epilepsy and Seizures that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 453 participants, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00088452, a Phase 3 study of Epilepsy and Seizures, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
Conditions Studied
Interventions
- DRUG Lamotrigine
- DRUG Ethosuximide
- DRUG Valproic acid
Study Locations (20)
New York
- Women and Children's Hospital of Buffalo - Buffalo
- NYU Comprehensive Epilepsy Center, Manhattan - New York
- Montefiore Medical Center - The Bronx
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Rainbow Babies & Children's Hospital - Cleveland
- Children's Hospital, Inc., PCTI - Columbus
California
- University of California at San Diego - La Jolla
- Mattel Children's Hospital at UCLA - Los Angeles
Florida
- Nemours Children's Clinic - Jacksonville
- Miami Children's Hospital - Miami
Alabama
- The Children's Hospital of Alabama - Birmingham
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital of Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2004-07 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088452
The ClinicalTrials.gov registry entry for NCT00088452 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (52% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Lamotrigine is the first listed.
NCT00088452 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT00088452 about?
NCT00088452 is a clinical study titled "Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study". The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
What is the current status of trial NCT00088452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2004-07. Estimated completion is 2016-08-31.
What conditions does trial NCT00088452 study?
This clinical trial studies the following conditions: Epilepsy, Seizures, Childhood Absence Epilepsy, Petit Mal Epilepsy.
What interventions are being tested in trial NCT00088452?
The interventions under investigation include: Lamotrigine (DRUG), Ethosuximide (DRUG), Valproic acid (DRUG).
Who is sponsoring clinical trial NCT00088452?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00088452 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.